Comparing Alirocumab vs Evolocumab
| Alirocumab | Evolocumab |
|
|---|
| Alirocumab | Evolocumab |
|
|---|---|---|
|
Prescription only
Prescribed for Cardiovascular Risk Reduction, High Cholesterol - Familial Homozygous, High Cholesterol - Familial Heterozygous, High Cholesterol. Alirocumab may also be used for purposes not listed... View more |
Prescription only
Prescribed for High Cholesterol - Familial Heterozygous, Cardiovascular Risk Reduction, High Cholesterol - Familial Homozygous, High Cholesterol. Evolocumab may also be used for purposes not listed... View more |
Related suggestions High Cholesterol
Cardiovascular Risk Reduction
High Cholesterol, Familial Heterozygous
High Cholesterol, Familial Homozygous
|
| More about Alirocumab | More about Evolocumab | |
| Ratings & Reviews | ||
|
Alirocumab has an average rating of 6.2 out of 10 from a total of 315 ratings on Drugs.com. 48% of reviewers reported a positive effect, while 31% reported a negative effect. |
Evolocumab has an average rating of 5.4 out of 10 from a total of 733 ratings on Drugs.com. 40% of reviewers reported a positive effect, while 43% reported a negative effect. |
|
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||
View all Alirocumab side effects |
View all Evolocumab side effects |
|
| Drug Class | ||
| Generic Availability | ||
|
N/A |
N/A |
|
| Pricing and Coupons * Prices are without insurance | ||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
|
| Dosage Forms | ||
|
N/A |
N/A |
|
| Brand Names | ||
| Praluent | Repatha | |
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||
|
480 hours |
408 hours |
|
| CSA Schedule 1 View glossary of CSA terms | ||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
|
| Pregnancy Category | ||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
|
| Drug Interactions | ||
|
A total of 3 drugs are known to interact with Alirocumab:
|
A total of 3 drugs are known to interact with Evolocumab:
|
|
| Alcohol/Food/Lifestyle Interactions | ||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
| Disease Interactions | ||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
| First Approval Date | ||
|
July 24, 2015 |
N/A |
|
| WADA Class View classifications | ||
|
N/A |
N/A |
|
| More Information | ||
| Patient Resources | ||
| Professional Resources | ||
| Related Treatment Guide | ||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.